跳至主要内容
临床试验/NCT04482777
NCT04482777尚未招募不适用

IL37,Tlymphocytes ,NK Cells in Pathogenesis of Immune Thrombocytopenia.

Assiut University0 个研究点目标入组 90 人开始时间: 2023年7月30日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
尚未招募
入组人数
90
主要终点
To decrease the immunity complications in ITP patients

研究概览

简要总结

To evaluate the role of IL37 in pathogenesis of ITP and to study the relation between IL37,Tlymphocytes,NK cells in ITP

详细描述

Idiopathic thrombocytopenia or immune thrombocytopenia (ITP) is a hematological condition which is characterized by a low platelet count of less than 100 x 109L . Symptoms of ITP can vary but tend to be symptoms of thrombocytopenia in general, such as petechiae, purpura, mucosal bleeding and in the most severe cases fatal intracranial hemorrhage(1,2) Interleukin (IL)-37, a novel anti-inflammatory cytokine previously known as interleukin-1 family member 7 before it was renamed, has a pivotal role in the suppression of immune responses (3,4). IL-37 is widely expressed in several types of cells, tissues and organs, including peripheral blood mononuclear cells (PBMCs) (5). The major role of IL-37 is to decrease excessive inflammation in innate and adaptive immune diseases, mainly by inhibiting the expression, production and function of pro-inflammatory cytokines, including IL-1α, IL-6, tumor necrosis factor (TNF) and macrophage inflammatory protein-2. The abundance of these cytokines has been reported to increase with the silencing of endogenous IL-37 in human blood cells (3,6).Aberrant expression of IL-37 has been observed in several inflammatory and autoimmune diseases However, the role of IL-37 in ITP has remained elusive. Immune thrombocytopenia pathogenesis is a complicated process. T cell immune abnormalities are involved in ITP pathogenesis. These abnormalities include platelet auto-antigen reactive cytotoxic T cells, abnormal numbers and functions of T regulatory cells, loss of Th1/Th2 balance, megakaryocyte maturation abnormalities and abnormal T cell anergy.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
2 Years 至 60 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with ITP (moderate and sever) different age group.

排除标准

  • Patients with stroke and myocardial infarction,malignant tumors or pregnancy.

研究组 & 干预措施

ITP

Patient newly diagnosied with ITP

干预措施: Corticosteriod for treated patients (Drug)

Treated

Patients with ITP recived treatment

干预措施: Corticosteriod for treated patients (Drug)

Control

Healthy people

干预措施: Corticosteriod for treated patients (Drug)

结局指标

主要结局

To decrease the immunity complications in ITP patients

时间窗: Baseline

Early detection of immunity complications in ITP patients

To decrease case fatality rate

时间窗: Baseline

Early detection of immunity complication will decrease mortality rate

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Asmaa Mohamed Elsayed

Resident physician

Assiut University

相似试验